Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Sandoz Group AG

Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.

Novartis completes Sandoz spinoff

Basel, October 4, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company.

Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines

Ad hoc announcement pursuant to Art. 53 LR  Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange Spin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicines Novartis pipeline one of the industry's most competitive, focused on key next-generation platforms and four core therapeutic areas Company reiterates guidance for FY 2023, with sales expected to grow high single digits and core operating income low double digits to mid-teens 1 Novartis to maintain consistent approach to capital allocation priorities including share buy-back and continued strong and growing dividend policy, with no re-basing after the Sandoz Spin-off Basel, October 4, 2023 — Novartis today completed the Spin-off of Sandoz, its Generics and Biosimilars business, through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (ADRs), with each holder receiving one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs, held at the close of business on October 3, 2023.

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.

Novartis (NVS) Announces Positive Data on Kidney Disease Drug

Novartis AG is considering selling a part of its radiopharmaceuticals business, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

Novartis considers selling radiopharma unit's assets - Bloomberg News

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

Merck

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

Eli Lilly

Pfizer

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

Drugmakers sign on to negotiate Medicare prices under protest

Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction 1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system 2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide 5–9 Novartis plans to review interim results with FDA to enable a potential regulatory submission for accelerated approval; study continues with final readout (24 months) in 2025 4 APPLAUSE-IgAN is the third positive Phase III trial for iptacopan and development program is ongoing across five indications; regulatory review is underway for paroxysmal nocturnal hemoglobinuria (PNH) in the US and EU 10,11 Basel, October 2, 2023 — Novartis today announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months1.

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potential additional milestone payments.

Novartis completes divestment of ‘front of eye' ophthalmology assets

British American Tobacco

Diageo

SAP SE

Sanofi

TotalEnergies SE

It was nice while it lasted, but the AI-driven stock market rally is rapidly running out of gas.

The US Stock Market Could Crack in October: 6 ‘Strong Buy' European Dividend Aristocrats to Buy Now

Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.

Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar

Novartis' core EPS payout ratio is poised to come in at around 51% in 2023. The Swiss drugmaker grew at a solid clip in the first half of this year. The company enjoys an AA- credit rating from ratings agency S&P.

Novartis: Buy This Dividend Aristocrat For Consistent Income

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.

Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study

Novo Nordisk

AstraZeneca

Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over the long-term, we expect investors to reward earnings upgrade stories - Novo Nordisk, Novartis, AstraZeneca - in the near-term,” it said.

Morgan Stanley sees biopharma sector as a 'safe haven'

Biogen

bluebird bio

BioMarin Pharmaceutical

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Regeneron Pharmaceuticals

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Novartis on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month.

Novartis confirms Sandoz spin-off for October 4, 2023

Basel, September 25, 2023 — Today, Novartis announced the Phase III NETTER-2 trial with Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) met its primary endpoint. First line treatment with Lutathera in combination with long-acting octreotide demonstrated a significant improvement in progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose long-acting octreotide alone1,2. No new or unexpected safety findings were observed in the study and data are consistent with the already well-established safety profile of Lutathera1 - 4.

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Basel, September 25, 2023 — Novartis today confirmed plans for the 100% Spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023.

Novartis confirms Sandoz Spin-off for October 4, 2023

BeiGene

Kezar Life Sciences Inc

Ocular Therapeutix

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis.

BeiGene regains rights for cancer drug after Novartis deal termination

Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.

Novartis' (NVS) Shareholders Approve Sandoz Separation

Novartis (NYSE: NVS ) stock is rising higher on Friday after the company announced approval for the spinoff of its generic drugs business Sandoz. Novartis conducted a shareholder vote on Friday seeking approval for the spinoff of Sandoz.

NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff

Basel, September 15, 2023 — At an Extraordinary General Meeting held today, Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis.

Novartis shareholders approve the proposed 100% Spin-off of Sandoz

Novartis shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the proposal.

Novartis shareholders vote in favour of Sandoz spin-off

Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America. The company discontinues the development of GT005 in geographic atrophy.

Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar

News for Novartis Stock (NVS)